Mahana obtains marketing authorization for IBS digital therapeutic
Click Here to Manage Email Alerts
Parallel, a prescription digital therapeutic developed by Mahana Therapeutics for the treatment of irritable bowel syndrome, received marketing authorization from the FDA, according to a company press release.
The 3-month digital program uses cognitive behavioral therapy to help adults change factors that might contribute to IBS.
“Parallel provides adult patients suffering from any subtype of IBS with a clinically validated, digitally delivered, cognitive behavioral therapy-based complementary treatment,” Emeran Mayer, MD, a distinguished professor at UCLA, and member of Mahana’s clinical advisory board, said in the release. “Cognitive behavioral therapy has increasingly been incorporated into gastrointestinal patient care, and this digital model increases access to this important treatment approach. Prescription digital therapeutics, working in ‘parallel’ with medications and other treatments represent an exciting new frontier in medicine.”
The program showed positive results in a randomized controlled trial comprising more than 550 patients with IBS. After 3 months of treatment, patients who used Parallel experienced reductions in severity of IBS symptoms.
Collapse
Click Here to Manage Email Alerts